{"id":"https://openalex.org/W4362490952","doi":"https://doi.org/10.1158/1535-7163.22520763.v1","title":"Supplementary Figures S1-S2 and Supplementary Table S1-S2 from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models","display_name":"Supplementary Figures S1-S2 and Supplementary Table S1-S2 from Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362490952","doi":"https://doi.org/10.1158/1535-7163.22520763.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22520763.v1","doi":"https://doi.org/10.1158/1535-7163.22520763.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22520763.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1535-7163.22520763.v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029089146","display_name":"Anita Kulukian","orcid":"https://orcid.org/0009-0001-5590-706X","observed_orcids":["https://orcid.org/0009-0001-5590-706X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita Kulukian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018707169","display_name":"Patrice Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrice Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Janelle Taylor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janelle Taylor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054365671","display_name":"Robert Rosler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Rosler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006772600","display_name":"Peter W. de Vries","orcid":"https://orcid.org/0000-0001-9710-8752","observed_orcids":["https://orcid.org/0000-0001-9710-8752"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter de Vries","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012766763","display_name":"Daniel Watson","orcid":"https://orcid.org/0000-0001-7841-6637","observed_orcids":["https://orcid.org/0000-0001-7841-6637"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Watson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046549002","display_name":"Andres Forero","orcid":"https://orcid.org/0000-0002-1360-1695","observed_orcids":["https://orcid.org/0000-0002-1360-1695","https://orcid.org/0000-0001-5161-8319"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andres Forero-Torres","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Scott Peterson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Peterson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tucatinib","display_name":"tucatinib","score":1.0},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.8410000205039978},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8149999976158142},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9900000095367432},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7179999947547913},{"id":"https://openalex.org/keywords/solid-tumor-models","display_name":"solid tumor models","score":0.5070000290870667},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.9810000061988831},{"id":"https://openalex.org/keywords/her2-phosphorylation","display_name":"HER2 phosphorylation","score":0.7590000033378601},{"id":"https://openalex.org/keywords/egfr-phosphorylation","display_name":"EGFR phosphorylation","score":0.8619999885559082},{"id":"https://openalex.org/keywords/neratinib","display_name":"neratinib","score":0.9300000071525574},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":1.0},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.5649999976158142}],"concepts":[{"id":"https://openalex.org/C2779413316","wikidata":"https://www.wikidata.org/wiki/Q6995920","display_name":"Neratinib","level":5,"score":0.8861451745033264},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7465139627456665},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.542877733707428},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.5208364129066467},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4495099186897278},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39987024664878845},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2580229938030243},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22252273559570312},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.21612751483917236},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.07676336169242859},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.07147535681724548}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.22520763.v1","doi":"https://doi.org/10.1158/1535-7163.22520763.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22520763.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22520763","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_S1-S2_and_Supplementary_Table_S1-S2_from_Preclinical_Activity_of_HER2-Selective_Tyrosine_Kinase_Inhibitor_Tucatinib_as_a_Single_Agent_or_in_Combination_with_Trastuzumab_or_Docetaxel_in_Solid_Tumor_Models/22520763","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22520763.v1","doi":"https://doi.org/10.1158/1535-7163.22520763.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22520763.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6000000238418579}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4387015371","https://openalex.org/W3015126839","https://openalex.org/W4362491062","https://openalex.org/W3083145800","https://openalex.org/W4387015361","https://openalex.org/W4387015266","https://openalex.org/W4283380987","https://openalex.org/W4387015268","https://openalex.org/W3013924824","https://openalex.org/W4387015269"],"abstract_inverted_index":{"Supplementary":[0,17,35,46],"Figure":[1,18],"S1:":[2,37],"Comparative":[3],"potency":[4],"of":[5,21],"tucatinib,":[6,22],"neratinib,":[7],"and":[8,13],"lapatinib":[9],"in":[10,31,53],"cellular":[11],"HER2":[12,42,49],"EGFR":[14],"phosphorylation":[15],"assays;":[16],"S2:":[19],"Effect":[20],"trastuzumab,":[23],"or":[24],"combination":[25],"treatment":[26],"on":[27],"mouse":[28],"body":[29],"weight":[30],"HER2+":[32],"PDX":[33,54],"models;":[34],"Table":[36,47],"Tucatinib":[38],"activity":[39],"correlates":[40],"with":[41],"surface":[43],"receptor":[44],"density;":[45],"S2.":[48],"copy":[50],"number":[51],"variation":[52],"models":[55]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-04-05T00:00:00"}